138 related articles for article (PubMed ID: 38124386)
1. A study of collagen refractility in dermatofibroma and dermatofibrosarcoma protuberans using diffractive microscopy.
Brailsford C; Khamdan F; Dirr MA; Sagut P; Nietert PJ; Elston D
J Cutan Pathol; 2024 Apr; 51(4):306-310. PubMed ID: 38124386
[TBL] [Abstract][Full Text] [Related]
2. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
4. Dermatofibroma Versus Dermatofibrosarcoma Protuberans: A Nuclear Morphology Study.
Khamdan F; Brailsford C; Dirr MA; Sagut P; Nietert PJ; Elston D
Am J Dermatopathol; 2023 Sep; 45(9):631-634. PubMed ID: 37625803
[TBL] [Abstract][Full Text] [Related]
5. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
6. CD99 expression in dermatofibrosarcoma protuberans and dermatofibroma.
Kazlouskaya V; Malhotra S; Kabigting FD; Lal K; Elston DM
Am J Dermatopathol; 2014 May; 36(5):392-6. PubMed ID: 24247571
[TBL] [Abstract][Full Text] [Related]
7. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
Kubo M; Ihn H; Yamane K; Tamaki K
Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896
[TBL] [Abstract][Full Text] [Related]
8. [Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans].
Xiong Y; Guo H; Zhang S; Zhang B; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):395-400. PubMed ID: 18677387
[TBL] [Abstract][Full Text] [Related]
9. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
[TBL] [Abstract][Full Text] [Related]
10. IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Li J; Yu Y; Yang Y; Wang L; Cao J; Liang X; Xiao X; Tu Y; Chen H
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):382-5. PubMed ID: 21492256
[TBL] [Abstract][Full Text] [Related]
11. The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans.
Maekawa T; Jinnin M; Ohtsuki M; Ihn H
Eur J Dermatol; 2011; 21(4):534-8. PubMed ID: 21697041
[TBL] [Abstract][Full Text] [Related]
12. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
[TBL] [Abstract][Full Text] [Related]
13. Overrepresentation of 17q22-qter and 22q13 in dermatofibrosarcoma protuberans but not in dermatofibroma: a comparative genomic hybridization study.
Nishio J; Iwasaki H; Ohjimi Y; Ishiguro M; Isayama T; Naito M; Iwashita A; Kikuchi M
Cancer Genet Cytogenet; 2002 Jan; 132(2):102-8. PubMed ID: 11850069
[TBL] [Abstract][Full Text] [Related]
14. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
15. Non-polarizable collagen in dermatofibrosarcoma protuberans: a useful diagnostic aid.
Barr RJ; Young EM; King DF
J Cutan Pathol; 1986 Oct; 13(5):339-46. PubMed ID: 3782573
[TBL] [Abstract][Full Text] [Related]
16. From Morphea to Dermatofibrosarcoma Protuberans.
Crnarić I; Šitum M; Delaš Aždajić M; Vučić M; Buljan M
Acta Dermatovenerol Croat; 2022 Sep; 30(2):113-115. PubMed ID: 36254545
[TBL] [Abstract][Full Text] [Related]
17. Identification of leukocyte-specific protein 1-positive cells: a clue to the cell of origin and a marker for the diagnosis of dermatofibroma.
Jin SY; Choi JS; Choi YL; Choi YL; Kim DH; Lee SH
Ann Dermatol; 2015 Apr; 27(2):157-62. PubMed ID: 25834354
[TBL] [Abstract][Full Text] [Related]
18. The involvement of fibroblast growth factor receptor signaling pathways in dermatofibroma and dermatofibrosarcoma protuberans.
Ishigami T; Hida Y; Matsudate Y; Murao K; Kubo Y
J Med Invest; 2013; 60(1-2):106-13. PubMed ID: 23614918
[TBL] [Abstract][Full Text] [Related]
19. Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans.
Chen YT; Chen WT; Huang WT; Wu CC; Chai CY
Kaohsiung J Med Sci; 2012 Oct; 28(10):545-9. PubMed ID: 23089320
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
West KL; Cardona DM; Su Z; Puri PK
Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
